Clinuvel Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLVLY research report →
Companywww.clinuvel.com
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
- CEO
- Philippe Jacques Wolgen
- IPO
- 2008
- Employees
- 100
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $348.84M
- P/E
- 14.06
- P/S
- 4.77
- P/B
- 1.84
- EV/EBITDA
- 10.18
- Div Yield
- 0.55%
Profitability
- Gross Margin
- 63.71%
- Op Margin
- 39.39%
- Net Margin
- 33.79%
- ROE
- 13.29%
- ROIC
- 11.07%
Growth & Income
- Revenue
- $95.02M · 7.76%
- Net Income
- $36.17M · 1.50%
- EPS
- $0.72 · 0.00%
- Op Income
- $45.73M
- FCF YoY
- 29.61%
Performance & Tape
- 52W High
- $9.00
- 52W Low
- $5.98
- 50D MA
- $6.78
- 200D MA
- $7.56
- Beta
- 0.60
- Avg Volume
- 1.69K
Get TickerSpark's AI analysis on CLVLY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CLVLY Coverage
We haven't published any research on CLVLY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLVLY Report →